These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 25238935)

  • 1. Novel fusion transcripts associate with progressive prostate cancer.
    Yu YP; Ding Y; Chen Z; Liu S; Michalopoulos A; Chen R; Gulzar ZG; Yang B; Cieply KM; Luvison A; Ren BG; Brooks JD; Jarrard D; Nelson JB; Michalopoulos GK; Tseng GC; Luo JH
    Am J Pathol; 2014 Oct; 184(10):2840-9. PubMed ID: 25238935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of fusion gene transcripts in the blood samples of prostate cancer patients.
    Yu YP; Liu S; Nelson J; Luo JH
    Sci Rep; 2021 Aug; 11(1):16995. PubMed ID: 34417538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of recurrent fusion genes across multiple cancer types.
    Yu YP; Liu P; Nelson J; Hamilton RL; Bhargava R; Michalopoulos G; Chen Q; Zhang J; Ma D; Pennathur A; Luketich J; Nalesnik M; Tseng G; Luo JH
    Sci Rep; 2019 Jan; 9(1):1074. PubMed ID: 30705370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
    Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
    Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
    Brockman JA; Alanee S; Vickers AJ; Scardino PT; Wood DP; Kibel AS; Lin DW; Bianco FJ; Rabah DM; Klein EA; Ciezki JP; Gao T; Kattan MW; Stephenson AJ
    Eur Urol; 2015 Jun; 67(6):1160-1167. PubMed ID: 25301759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression signature of Gleason score is associated with prostate cancer outcomes in a radical prostatectomy cohort.
    Jhun MA; Geybels MS; Wright JL; Kolb S; April C; Bibikova M; Ostrander EA; Fan JB; Feng Z; Stanford JL
    Oncotarget; 2017 Jun; 8(26):43035-43047. PubMed ID: 28496006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulation of Talin-1 expression associates with advanced pathological features and predicts lymph node metastases and biochemical recurrence of prostate cancer.
    Xu N; Chen HJ; Chen SH; Xue XY; Chen H; Zheng QS; Wei Y; Li XD; Huang JB; Cai H; Sun XL
    Medicine (Baltimore); 2016 Jul; 95(29):e4326. PubMed ID: 27442684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A qualitative transcriptional signature for predicting the biochemical recurrence risk of prostate cancer patients after radical prostatectomy.
    Li X; Huang H; Zhang J; Jiang F; Guo Y; Shi Y; Guo Z; Ao L
    Prostate; 2020 Apr; 80(5):376-387. PubMed ID: 31961962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression panel predicts metastatic-lethal prostate cancer outcomes in men diagnosed with clinically localized prostate cancer.
    Rubicz R; Zhao S; Wright JL; Coleman I; Grasso C; Geybels MS; Leonardson A; Kolb S; April C; Bibikova M; Troyer D; Lance R; Lin DW; Ostrander EA; Nelson PS; Fan JB; Feng Z; Stanford JL
    Mol Oncol; 2017 Feb; 11(2):140-150. PubMed ID: 28145099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of two gene panels for prostate cancer diagnosis and patient risk stratification.
    Xiao K; Guo J; Zhang X; Feng X; Zhang H; Cheng Z; Johnson H; Persson JL; Chen L
    Tumour Biol; 2016 Aug; 37(8):10115-22. PubMed ID: 26820133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative analysis of a panel of gene expression in prostate cancer--with emphasis on NPY expression analysis.
    Liu AJ; Furusato B; Ravindranath L; Chen YM; Srikantan V; McLeod DG; Petrovics G; Srivastava S
    J Zhejiang Univ Sci B; 2007 Dec; 8(12):853-9. PubMed ID: 18257117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between PSA density and pathologically significant prostate cancer: The impact of prostate volume.
    Omri N; Kamil M; Alexander K; Alexander K; Edmond S; Ariel Z; David K; Gilad AE; Azik H
    Prostate; 2020 Dec; 80(16):1444-1449. PubMed ID: 32970856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of cell cycle-regulated genes and prostate cancer prognosis in a population-based cohort.
    Rubicz R; Zhao S; April C; Wright JL; Kolb S; Coleman I; Lin DW; Nelson PS; Ostrander EA; Feng Z; Fan JB; Stanford JL
    Prostate; 2015 Sep; 75(13):1354-62. PubMed ID: 25990700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of fusion transcripts in the serum samples of patients with hepatocellular carcinoma.
    Yu YP; Tsung A; Liu S; Nalesnick M; Geller D; Michalopoulos G; Luo JH
    Oncotarget; 2019 May; 10(36):3352-3360. PubMed ID: 31164957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Golgi phosphoprotein 3 expression predicts poor prognosis in patients with prostate cancer undergoing radical prostatectomy.
    Zhang L; Guo F; Gao X; Wu Y
    Mol Med Rep; 2015 Jul; 12(1):1298-304. PubMed ID: 25760033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth.
    Hu BR; Fairey AS; Madhav A; Yang D; Li M; Groshen S; Stephens C; Kim PH; Virk N; Wang L; Martin SE; Erho N; Davicioni E; Jenkins RB; Den RB; Xu T; Xu Y; Gill IS; Quinn DI; Goldkorn A
    Prostate; 2016 May; 76(6):597-608. PubMed ID: 26771938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy.
    Geybels MS; Wright JL; Bibikova M; Klotzle B; Fan JB; Zhao S; Feng Z; Ostrander EA; Lin DW; Nelson PS; Stanford JL
    Clin Epigenetics; 2016; 8():97. PubMed ID: 27651837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term oncological outcomes of apical positive surgical margins at radical prostatectomy in the Shared Equal Access Regional Cancer Hospital cohort.
    Wadhwa H; Terris MK; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Freedland SJ; Abern MR
    Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):423-428. PubMed ID: 27698440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
    Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
    BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear Shape and Architecture in Benign Fields Predict Biochemical Recurrence in Prostate Cancer Patients Following Radical Prostatectomy: Preliminary Findings.
    Lee G; Veltri RW; Zhu G; Ali S; Epstein JI; Madabhushi A
    Eur Urol Focus; 2017 Oct; 3(4-5):457-466. PubMed ID: 28753763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.